Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
127,672,444
-
Number of holders
-
165
-
Total 13F shares, excl. options
-
63,890,305
-
Shares change
-
-264,042
-
Total reported value, excl. options
-
$3,654,164,157
-
Value change
-
-$7,921,158
-
Put/Call ratio
-
57%
-
Number of buys
-
80
-
Number of sells
-
-71
-
Price
-
$57.20
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q4 2020
194 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q4 2020.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 165 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63,890,305 shares
of 127,672,444 outstanding shares and own 50% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (10,508,111 shares), BlackRock Inc. (6,014,948 shares), VANGUARD GROUP INC (5,541,825 shares), HILLHOUSE CAPITAL ADVISORS, LTD. (5,028,289 shares), PRICE T ROWE ASSOCIATES INC /MD/ (3,045,329 shares), JENNISON ASSOCIATES LLC (2,772,420 shares), STATE STREET CORP (2,430,753 shares), FARALLON CAPITAL MANAGEMENT LLC (2,275,000 shares), VICTORY CAPITAL MANAGEMENT INC (1,909,977 shares), and Cormorant Asset Management, LP (1,866,108 shares).
This table shows the top 165 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.